Inovio launches Phase I/IIa trial for MERS infection in South Korea
US-based immunotherapy firm Inovio Pharmaceuticals has launched a Phase I/IIa clinical trial of its vaccine candidate GLS-5300 to treat MERS (Middle East Respiratory Syndrome) infection in South Korea.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Clinical Trials | Immunotherapy | MERS | Middle East Health | Pharmaceuticals | Respiratory Medicine | South Korea Health | Vaccines